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Abstract 
Flecainide suppresses cardiac tachyarrhythmias including paroxysmal atrial fibrillation, supraventricular tachycardia, 
arrhythmic long QT syndromes (LQTS), as well as the Ca2+-mediated, catecholaminergic polymorphic ventricular, 
tachycardia (CPVT). However, flecainide can also exert pro-arrhythmic effects most notably following myocardial 
infarction and when used to diagnose Brugada Syndrome (BrS). These divergent actions result from its physiological 
and pharmacological actions at multiple, interacting, levels of cellular organisation. These were studied in murine 
genetic models with modified Nav channel or intracellular ryanodine receptor (RyR2)-Ca2+ channel function. 
Flecainide accesses its transmembrane Nav1.5 binding site during activated, open, states producing a use-dependent 
antagonism. Closing either activation or inactivation gates traps flecainide within the pore. An early peak INa related to 
Nav channel activation followed by rapid de-activation drives action potential (AP) upstrokes and their propagation. 
This is diminished in pro-arrhythmic conditions reflecting loss of Nav1.5 function such as BrS, accordingly 
exacerbated by flecainide challenge. Contrastingly, pro-arrhythmic effects attributed to prolonged AP 
recovery by abnormal late INaL following gain-of-function Nav1.5 modifications in LQTS3 are reduced by flecainide. 
Anti-arrhythmic effects of flecainide that reduce triggering in CPVT models mediated by sarcoplasmic reticular Ca2+ 
release could arise from its primary Nav channel actions indirectly decreasing [Ca
2+
]i through a reduced [Na
+
]i and/or 
direct open-state RyR2-Ca2+ channel antagonism. The consequent [Ca2+]i alterations could also modify AP 
propagation velocity and therefore arrhythmic substrate through its actions on Nav1.5 function. This is consistent with 
the paradoxical differences between flecainide actions upon Na+ currents, AP conduction and arrhythmogenesis under 
circumstances of normal and increased RyR2 function.  
 
 
Abbreviations 
AP- Action potential 
APD- Action potential duration 
AV- Atrioventricular 
BrS- Brugada syndrome 
CaM- Calmodulin 
CaMKII- Calmodulin Kinase II 
CASQ- Calsequestrin 
CAST- Cardiac Arrhythmia Suppression Trial 
CPVT- Catecholaminergic polymorphic ventricular tachycardia 
DAD- Delayed afterdepolarisation 
ECG- Electrocardiographic 
ICaL- L-type calcium current 
IKr- Rapidly activating delayed rectifier current  
IKs- Slowly activating delayed rectifier current  
INa- Inward sodium current 
INaL- Late inward sodium current 
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Ito- Transient outward current 
LQTS- Long QT syndrome 
NCX- Sodium-Calcium exchanger 
PR- standard P to R interval on ECG recording 
QRS- standard QRS interval on ECG recording 
QT- standard QT interval on ECG recording 
RyR- Ryanodine receptor  
SR- Sarcoplasmic reticular 
VT- Ventricular tachycardia 
 
 
Introduction  
Cardiac arrhythmias constitute an important clinical and public health problem. Pharmacological modes of action, 
effectiveness, and specific indications of anti-arrhythmic agents are therefore of particular interest (Huang, 2017). This 
is particularly so when they exert contrasting, beneficial, ineffective, or even harmful, actions dependent upon the 
particular physiological or clinical circumstances under which they are applied. The class Ic anti-arrrhythmic agent 
flecainide ((RS)-N-(piperidin-2-ylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)benzamide); C17H20F6N2O3) (Fig. 1A) 
originated from explorations of 2,5-bis(2,2,2-trifluoroethoxy)benzamide compounds as pharmaceutical candidates. 
Early studies in intact canine hearts demonstrated that flecainide markedly increased ventricular fibrillation thresholds 
following supraventricular beats and ventricular premature beats and slowed ectopic atrial and ventricular pacemakers. 
It also prolonged atrioventricular (AV) conduction (at plasma concentrations of 0.4 to 0.7 µg ml
-1
) and overall 
excitation delay (at >6.5 µg ml-1) (Hodess et al., 1979). Standard microelectrode techniques attributed these findings to 
reductions in maximal rates of rise of the action potential (AP), (dV/dt)max, in the absence of stimulation. These 
became accentuated during stimulus trains with stimulus intervals <4800 ms over 20 to 50 beats in guinea-pig 
ventricle even at normal resting potentials. Flecainide also produced negative steady-state shifts in the relationship 
between (dV/dt)max and membrane potential of possible clinical relevance in ischaemic states (Campbell and Vaughan 
Williams, 1983).  
 
In common with other anti-arrhythmic agents, flecainide also affected cardiac contractile activation processes, dose-
dependently decreasing peak left ventricular isovolumic pressure and peak isovolumic rate of pressure generation, 
(dP/dt)max, in intact rat hearts (Hoffmeister et al., 1987; Fernandes et al., 2014). These findings correlated with 
decreased aequorin luminescence and isometric tension signals in isolated canine ventricular trabeculae and reduced 
Ca
2+
 current, ICaL, in isolated myocytes from the same ventricle (Kihara et al., 1996). These findings translated to 
effects on peak isometric contractile force and maximal rates of force development and decline in human ventricular 
muscle (Lynch et al., 2013). These results suggest multiple, potentially interacting, actions requiring analysis at the 
systems level, whose mechanisms and pharmacological implications are reviewed in this present article. 
 
Anti-arrhythmic effects of flecainide 
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Initial clinical studies reported encouraging effects of flecainide on occurrences of premature ventricular or atrial 
contractions in arrhythmic patients whilst minimally altering their electrocardiographic (ECG) PR, QRS, or QT 
intervals, or producing other side effects (Somani, 1980). The compound has a high bioavailability. Its amide group 
has a pKa of ~9.3 (Liu et al., 2003) and so it is 99% protonated as a water soluble monovalent cation at physiological 
pH. Peak blood levels are reached 1 to 6 hours after oral ingestion (Smith, 1985). Its plasma half-life is 12 to 27 hours 
(Padrini et al., 1993). Subsequent reports similarly confirmed that even low (100 mg twice daily) flecainide doses 
reduced both triggering events represented by premature ventricular contractions (Abitbol et al., 1983), and substrate 
reflected in the appearance of ventricular tachycardia (VT) following programmed electrical stimulation, during 
Holter monitoring and electrophysiological testing (Somberg and Tepper, 1986). Its pharmacokinetics permitted oral 
administration (Anderson et al., 1981; Pottage, 1983; Holmes and Heel, 1985). Orally administered flecainide also 
suppressed premature ventricular complexes, and ventricular tachycardia (Anderson et al., 1981) and proved 
acceptable for long term use (Meinertz et al., 1984).  
 
These findings led to use of flecainide in preventing and treating ventricular ectopic events and tachycardias, 
paroxysmal atrial fibrillation (Anderson et al., 1989) and supraventricular tachycardia, including AV nodal re-entrant 
tachycardia and Wolff-Parkinson-White syndrome (Henthorn et al., 1991; Pritchett et al., 1991). It was also beneficial 
for long QT syndromes particularly long QT syndrome type 3 (LQTS3), associated with gain-of-function Nav1.5 
mutations (Shimizu and Antzelevitch, 1999). Low-dose, oral flecainide consistently shortened corrected QT (QTc) 
intervals and normalised repolarisation T-wave patterns in LQTS3 patients with SCN5A-∆KPQ mutations (Windle et 
al., 2001; Moss et al., 2005), consistent with its application as a mutation-specific therapy for LQTS3 (Benhorin et al., 
2000). Flecainide was relatively free of adverse, particularly neurological and gastrointestinal, side effects at effective 
dose levels (Anderson et al., 1981; Pottage, 1983; Holmes and Heel, 1985). 
 
Pro-arrhythmic effects of flecainide: the CAST trial 
Through its long history of clinical therapeutic benefit, use of flecainide has been shadowed by pro-arrhythmic 
consequences under some clinical circumstances, particularly in the presence of ischaemic or morphological change. 
Ventricular tachyarrhythmias and severe bradycardia occur when its narrow therapeutic index is exceeded by frank 
overdose or with chronic cardiac disease. Such cases show increased PR and QRS intervals suggesting depressed 
conduction and signs and symptoms attributable to overt heart failure likely reflecting acutely decreased myocardial 
contractility (Winkelmann and Leinberger, 1987). An early study reported that 7 of 152 patients showed pro-
arrhythmic effects including ventricular tachycardia or ventricular fibrillation over a ~22 month period, similarly 
associated with increased PR intervals and widened QRS complexes rather than QTc prolongation (Nathan et al., 
1984). Additionally, in the Cardiac Arrhythmia Suppression Trial (CAST) anti-arrhythmic therapy with encainide, 
flecainide, or moricizine initially suppressed arrhythmia in 1727 of 2309 post-myocardial infarction patients with 
asymptomatic or mildly symptomatic ventricular arrhythmia during Holter recording. However, encainide or 
flecainide-treated patients showed a higher incidence (8.9%) of arrhythmic death than patients assigned to placebo 
(1.2%) over a 10 month follow-up (CAST Investigators, 1989; Echt et al., 1991; Greenberg et al., 1995). Finally, 
flecainide has proved pro-arrhythmic in individuals suspected of having BrS where it can unmask its characteristic 
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ECG findings, a fact used in its clinical diagnosis in equivocal cases (Gasparini et al., 2003; Wolpert et al., 2005; 
Meregalli et al., 2006). 
 
Nav channel activation and inactivation processes  
These multifarious actions of flecainide under different clinical circumstances may reflect arrhythmias being 
multicellular phenomena. They involve triggering mechanisms formed by spontaneous electrophysiological events 
occurring independently of the normal cardiac pacing process. In addition, the presence of arrhythmic substrate in the 
form of further electrophysiological abnormalities could perpetuate this arrhythmic event. These depend upon the 
electrophysiological stability of cellular excitation involving the interacting properties of numerous channel types, 
alterations in AP conduction between myocytes, and the effects of myocardial anatomy. Understanding the effects of 
flecainide therefore not only concern its actions at the molecular level, but also their systems-level consequences. It 
would then be necessary to consider interacting functional changes at the cellular, tissue and organ levels, and to 
correlate these with the targeted clinical outcome. The following sections explore the extent to which these diverse 
actions of flecainide under vari us disease paradigms are accounted for by its actions upon multiple interacting 
cellular targets, of which the most prominent are Nav channels.  
 
The Nav
 
channel function itself poses intrinsic complexities. First, it entails distinct activation and inactivation 
processes. Channel activation depends on mov ments of S4 α-helices predominantly in domains DI-III whose positive 
charges underly their voltage-sensing function (Catterall, 2012). This process drives the rapid initial, phase 0 
depolarisation that activates the cardiac AP as well as its propagation to neighbouring and previously quiescent 
regions. Channel inactivation results from similar voltage-sensitive movement of the S4 α-helix in domain DIV, 
which drives pore occlusion by the cytoplasmic III-IV linker (Kühn and Greeff, 1999). A further slow inactivation 
may involve further conformational changes in the α-subunit pore region (Ulbricht, 2005). Secondly, the resulting Na
+
 
current, INa, may include one or more current components each with different kinetics These might reflect either 
modulations in the function of individual cardiac Nav1.5 channels or distinct channel subpopulations (Saint et al., 
1992; Saint, 2009). An early peak INa related to Nav activation drives the rapid early AP upstroke, thereby generating 
local circuit currents underlying AP propagation, rapidly inactivating within a few milliseconds. The resulting 
membrane depolarisation activates a variety of further ion channels.  
 
In addition to INa inactivation, AP recovery initially involves activation of transient outward (Ito) currents. The initial 
Nav1.5-mediated depolarisation also activates plateau Ca
2+
 currents (ICaL) that locally elevate cytosolic [Ca
2+
] 
triggering RyR2-mediated sarcoplasmic reticular (SR) Ca2+ release and therefore mechanical activation, with 
consequences for Ca
2+
 homeostasis and possible reciprocal interactions with surface channel excitability. Finally a 
variety of voltage-gated K+ channels including the delayed rectifiers IKr and IKs, and the inwardly rectifying IK1, drives 
the final repolarisation restoring the resting potential. This recovery is opposed by late inward Na
+
 current, INaL, of 
magnitude ~1-2% of the peak INa, (Noble and Noble, 2006; Makielski, 2016). Although INaL shows a more negative (by 
-20 mV)  voltage dependence in its activation properties (Saint et al., 1992), its channel conductance, mean open times 
and selectivity properties are otherwise identical to the remaining INa (Ju et al., 1992). Increased INaL influences AP 
duration and the refractory period. Finally, with repolarisation to the resting potential, the Nav1.5 channels recover 
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their capacity for re-excitation, resulting in absolute and relative refractory periods. These respectively correspond to 
the time intervals over which the channels either cannot be re-excited whatever the stimulus intensity, or require 
increased stimulus amplitudes for such re-excitation. 
 
Molecular pharmacology of flecainide 
Studies of clinically occurring Nav1.5 variants implicated mutations in the IV-S6 helix as most commonly associated 
with altered responses to flecainide and overlapping interactions with other, similarly cationic and hydrophobic, local 
anaesthetics. They thus suggested that the flecainide binding site on Nav1.5 is close to this region (Fig. 2) 
(Viswanathan et al., 2001; Liu et al., 2002, 2003; Viswanathan and Balser, 2004; Fozzard et al., 2011). Other amino 
acid substitution studies revealed that only two IV-S6 residues affected Nav1.5 interactions with anaesthetics 
(Ragsdale et al., 1994; Yarov-Yarovoy et al., 2002; Hanck et al., 2009). In particular, unnatural amino acid 
mutagenesis showed that high-affinity binding of lignocaine highly depended upon cation-π interactions with 
phenylalanine-1759; it is possible that the positive charge of flecainide could similarly interact (Fig. 2A) (Ahern et al., 
2008).  Fig. 2B illustrates this region by docking flecainide into a proteobacterial homologue of Nav1.5 (NavRh) 
(Zhang et al., 2012). In this docked pose, flecainide occupies a hydrophobic cavity at the interface of adjacent subunits 
and makes contact with the important phenylalanine in IV-S6. 
 
Flecainide may have similar K
+
 channel, including Kv11.1, binding sites that also overlap with binding sites for other 
ligands, such as the structurally related propafenone (Fig. 1B). Binding is again heavily influenced by interactions 
with a phenylalanine residue in the S6 helix (Madeja et al., 2010; Melgari et al., 2015). These effects appeared to be 
mediated by charged rather than uncharged flecainide accessing the channel from the cell interior. Studies of its 
effects in IKR from expressed Kv11.1 containing a range of single site mutations suggested that flecainide binds low in 
the inner channel cavity (Melgari et al., 2015). These similarities suggest that flecainide binding is constrained even 
between receptor subtypes. Such shared sites of action are perhaps not surprising: elsewhere different members of the 
Cys-loop family of ligand-gated ion channels also share a common transmembrane binding site for anaesthetics 
(Forman et al., 1995; Nury et al., 2011). 
 
Nav channel antagonism by flecainide 
Flecainide acts upon the activated, open, state of Nav1.5 (Anno and Hondeghem, 1990; Nitta et al., 1992; Nagatomo 
et al., 2000) (Fig. 3A), gaining access to a transmembrane binding site where it blocks the pore, and inhibits INa (Liu et 
al., 2002, 2003) (Fig. 3B). INa inhibition takes place with a low-affinity (IC50 = 345 µM) during brief depolarising 
steps. However the affinity dramatically increases (IC50 = 7.4 µM) with increasing stimulation frequency as expected 
for use-dependent binding. This use-dependent antagonism occurs at concentrations as low as 0.5 µM and saturates at 
≥50 µM flecainide (Nitta et al., 1992). It is reflected in an increasing inhibition of INa (Fig. 4A, left panel), and a 
consequent shift in the dependence of INa inhibition towards lower flecainide concentrations under conditions of 
increasing pulsing frequency (Fig. 4A, right  panel)(Penniman et al., 2010). This accounts for progressive increases in 
AP refractory periods, decreases in (dV/dt)max and increases in APD with increasing stimulus frequencies in hearts of a 
range of species (Fig. 4B)(Wang et al., 1990). Consistent with this, in a non-inactivating Nav1.5 mutant, flecainide 
produced decays in INa with a timecourse suggesting a simple pore blocking mechanism (KD = 11 µM). Once bound, 
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flecainide reduces Nav channel open times (Grant et al., 2000). Flecainide binding to channels then inactivated by 
sustained depolarisation does not contribute to Nav channel inhibition (Nitta et al., 1992; Nagatomo et al., 2000; Liu et 
al., 2002; Wang et al., 2003). Flecainide action was not enhanced with sustained depolarisation producing channel 
inactivation (Ramos and O’Leary, 2004) 
 
Flecainide does not directly bind to closed or inactivated Nav channels but closing either the activation or the 
inactivation gate traps flecainide within the pore (Fig. 3C), slowing recovery of drug-bound channels at hyperpolarised 
voltages. Thus, flecainide slowed recovery of both rapidly inactivating (τ~81 s) and non-inactivating (τ~42 s) channels 
with hyperpolarisation. The mutation of a conserved isoleucine, SCN5A-I1756C, within the pore forming region 
(DIV- S6), accelerated recovery of both rapidly inactivating (τ ~ 12.6 s) and non-inactivating (τ ~ 7.4 s) channels. 
These observations suggest that flecainide is trapped rather than tightly bound within the pore when channels are 
closed or inactivated (Ramos and O’Leary, 2004).  
 
Contrasting actions of flecainide in ion channel models for arrhythmia  
Experimental studies suggest that some of the contrasting effects of flecainide reflect the differing mechanisms 
underlying arrhythmia in the particular models under study (Fig. 5). They suggest that flecainide exerts pro-
arrhythmic effects upon arrhythmic substrate attributable to compromised AP activation and propagation resulting 
from a reduced peak INa correspondingly compromising AP upstroke velocities, (dV/dt)max. This situation is likely in 
the Brugada syndrome (BrS), whose commonest genetic accompaniment is an inherited loss-of-function Nav1.5 
deficiency associated with increased risks of potentially fatal ventricular arrhythmias particularly in middle aged (40–
45 y) males (Brugada et al., 2002). It has been modelled in isolated murine heterozygotic Nav1.5 haplo-insufficient 
Scn5a+/- cardiac preparations (Papadatos et al., 2002). These preparations replicated clinically observed arrhythmic 
tendencies and attributed these to compromised AP conduction particularly following extrasystolic stimuli, findings 
that correlate with biophysical observations of a reduced peak INa (Martin et al., 2011b, 2012). Flecainide challenge 
also recapitulated clinical observations as it increased these ventricular arrhythmic tendencies (Stokoe et al., 2007a; 
Martin et al., 2010; Matthews et al., 2013). The altered balance between inward INa and outward Ito mediating early AP 
repolarisation would also be expected to increase the likelihood of pro-arrhythmic phase II re-entry phenomena (Lukas 
and Antzelevitch, 1996), although these would be made less likely as flecainide also increases effective refractory 
periods (Martin et al., 2011a). 
 
In contrast, flecainide exerts anti-arrhythmic effects under conditions associated with abnormal AP recovery, 
particularly when arising from increased INaL. The open channel antagonist nature of flecainide action on Nav1.5 could 
make it particularly effective on Nav channels showing prolonged dwell times, as with the increased INaL in LQTS3. 
Patch-clamp studies on the HEK293 expression system demonstrated that flecainide exerted a more marked tonic and 
use-dependent INa antagonism in Scn5a+/∆KPQ than wild-type (WT). Scn5a+/∆KPQ channels showed a greater use-
dependent antagonism of both peak INa and INaL than WT channels. In both cases, flecainide preferentially inhibited 
INaL (IC50 ~ 19 vs 44 µM) over peak INa (IC50 ~ 80 vs 127 µM) (Nagatomo et al., 2000).  
 
Page 7 of 51
British Pharmacological Society
British Journal of Pharmacology
For Peer Review
8 
 
In LQTS3, both AP prolongation and increased arrhythmic tendency is attributed to increased late Na+ current INaL and 
a consequent persistent Nav channel opening. This thus provides a pro-arrhythmic exemplar distinct from arrhythmia 
arising from deficient peak INa in BrS. Murine Scn5a+/∆KPQ hearts modeled this clinical arrhythmic phenotype. For 
example, isolated, Langendorff-perfused, Scn5a+/∆KPQ hearts showed increased arrhythmogenicity on programmed 
electrical stimulation. Their monophasic APs were prolonged, accounting for the observed increases in 
electrocardiographic QT intervals. Biophysical studies attributed these changes to increased INaL (Bennett et al., 1995; 
Nuyens et al., 2001; Head et al., 2005). This was accompanied by increased frequencies of early afterdepolarisation 
events that could potentially act as arrhythmic triggers (Damiano and Rosen, 1984; Wang et al., 1995a; Thomas et al., 
2008; Belardinelli et al., 2015). The latter have been attributed to elevations of [Na+]i promoting reverse mode Na
+-
Ca
2+
 exchanger (NCX) activity. This results in the pro-arrhythmic alterations in cellular Ca
2+
 homeostasis further 
discussed below (Shryock et al., 2013). The ventricles also showed altered transmural action potential duration (APD) 
gradients across the ventricular wall potentially providing arrhythmic substrate (January and Riddle, 1989; Sabir et al., 
2008; Horvath et al., 2013). Both these abnormalities and their associated arrhythmic tendencies were abolished by 
flecainide (Stokoe et al., 2007b; Sabir et al., 2008). This feature replicates clinically established anti-arrhythmic 
effects of flecainide in LQTS3 (Windle et al., 2001; Moss et al., 2005) thus further demonstrating that murine hearts 
provide useful models for the human condition.  
 
Occurrences of flecainide exerting pro- rather than anti-arrhythmic effects in LQTS3 have also been reported. 
However, these were observed when LQTS3 phenotypic features were combined with abnormalities normally 
associated with a Nav1.5 haplo-insufficient BrS, resulting in an overlap syndrome (Bezzina et al., 1999). The latter has 
been modelled by murine Scn5a+/1795insD hearts. In addition to the increased QTc intervals, bradycardia and 
bradycardic pauses expected from a LQTS3 phenotype, these showed increased PQ intervals, and QRS durations 
suggesting slowed ventricular conduction. Patch-clamped ventricular myocytes correspondingly showed increased AP 
durations and increased INaL. The voltage-dependences of activation, of steady-state rapid or slow inactivation, and of 
recovery from inactivation, were of normal Nav1.5. In addition, reduced peak INa and (dV/dt)max, correlated with multi-
electrode recordings in Langendorff-perfused hearts revealing slowed conduction of excitation (Remme et al., 2006).  
Overlap features were also shown by ageing Scn5a+/∆KPQ (Guzadhur et al., 2010; Wu et al., 2012). These findings 
could account for reports that flecainide produced ST-segment elevation characteristic of BrS in some LQT3 patients, 
suggesting that this Nav channel antagonist could paradoxically be pro-arrhythmic in LQTS3 in the presence of 
accompanying conduction abnormalities (Priori et al., 2000). Such dual phenotypes have also been attributed to 
myocardial heterogeneities (Clancy and Rudy, 2002) or simultaneous shifts in Nav1.5 inactivation characteristics 
(Grant et al., 2002). They could also arise from differences in the effects of flecainide upon inactivation gating. Both 
Scn5a+/1795insD and Scn5a+/∆KPQ channels expressed in tsA-201 cells exhibited modified inactivation gating from 
the closed channel state. However, flecainide antagonised INaL to different extents in the sequence WT < 
Scn5a+/∆KPQ < Scn5a+/1795insD.  Scn5a-+/1795insD channels further showed delayed recoveries from inactivation 
further exacerbated by flecainide (Viswanathan et al., 2001). 
 
Further complexities arise because Nav channels do not occur as isolated molecules in the plasma membrane, but 
instead are anchored within larger, extended multi-component complexes. Examples of such associated proteins 
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include auxiliary Nav channel β subunits (Cusdin et al., 2010), cytoskeletal proteins  (Jeevaratnam et al., 2016; Huang, 
2017) and other ion channels such as the inward rectifier Kir2.1 (Willis et al., 2015). These proteins can influence Nav 
channel gating behaviour both directly through protein-protein contacts and indirectly by affecting surface expression 
and trafficking (Abriel and Kass, 2005; Cusdin et al., 2008; Abriel et al., 2015). 
 
 Relatively little attention has been paid to how this supra-molecular channel clustering could influence flecainide 
pharmacology. To our knowledge, the only example where such effects on flecainide behaviour were studied is the 
case of the auxiliary Nav β3 subunit, the product of the Scn3b gene  (Hakim et al., 2010). The β3 subunit is expressed 
in heart and modulates Nav1.5 gating (Yu et al., 2005). Patch-clamped Scn3b-/- murine cardiomyocytes showed 
reduced INa likely reflecting reduced Nav1.5 trafficking into the surface membrane. This was combined with negative 
shifts in Nav1.5 inactivation characteristics that would be expected to reduce INaL but shorten refractory periods. The 
genetic variant accordingly shows arrhythmic phenotypes resembling that of the Scn5a+/- murine model (Hakim et al., 
2008). Indeed, several mutations in SCN3B are associated with inherited cardiac arrhythmias in humans (Namadurai et 
al., 2015).  
 
Curiously however, in Scn3b-/- hearts, flecainide produced reduced arrhythmic incidences combined with prolonged 
refractory periods and shortened APDs (Hakim et al., 2010). This is in direct contrast to its effects in Scn5a+/- mice 
(see above). The reasons for this difference are unclear, but they further confirm suggestions that flecainide exerts dual 
pro- and anti-arrhythmic actions through effects on both conduction and refractoriness. Thus, in the case of Scn5a+/- 
hearts the negative conduction velocity effects predominate in producing arrhythmia exacerbated by flecainide. In the 
case of LQTS3, refractoriness and recovery effects predominate in producing arrhythmia reduced by flecainide. The 
presence or absence of β3 subunits may differentially modify these two competing effects so that an anti-arrhythmic 
effect predominates.  
 
How this might work is currently unknown and will probably require detailed structural insights into how the β3 
subunit interacts and modulates the Nav1.5 α subunit. The β3 subunit contains a single extracellular immunoglobulin 
domain, a single-pass transmembrane domain and an intracellular domain and interacts with Nav1.5 through both its 
extracellular and intracellular domains (Namadurai et al., 2015). It is striking however, that neither of these two 
interaction sites are close to the flecainide binding site on Nav1.5 (Fig.  2B). This suggests that the β3 subunit most 
likely modulates the effects of flecainide on Nav1.5 indirectly, either by affecting channel opening probability or by 
its known effects on Nav1.5 oligomerisation (Namadurai et al., 2014, 2015). 
 
K
+
 channel antagonism by flecainide 
Flecainide also acts on K+ channels (Figure 6). At <10 µM it inhibits rapid K+ current, IKR, tails that followed voltage 
clamp pulses to +30 mV in the HEK293 expression system. The effect was most noticeable in the steepest part of the 
IKR  (Kv11.1, hERG) activation curve reflecting a voltage-dependent inhibition consistent with a rapid open channel 
state IKR antagonism similar to that described for INa (Paul et al., 2002). Flecainide (>10 µM) also inhibits rapid 
transient outward (Kv4.2) currents, Itof, in both native cells (Slawsky and Castle, 1994) and heterologous expression 
systems (Rolf et al., 2000), to extents increasing with channel inactivation and consistent with its higher affinity for 
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the inactivated state of Kv4.2 (Wang et al., 1995b). Finally, flecainide  (~100 µM) inhibits ultrarapid delayed rectifier 
(Kv1.5) current, IKur (Tamargo et al., 2004; Herrera et al., 2005) 
 
Anti-arrhythmic effects of flecainide in catecholaminergic polymorphic ventricular tachycardia (CPVT) 
More recently, flecainide proved to exhibit potential therapeutic efficacy in the Ca2+-mediated catecholaminergic 
polymorphic ventricular tachycardia (CPVT). CPVT is predominantly associated with genetic abnormalities involving 
the cardiac ryanodine receptor type 2 sarcoplasmic reticular (SR) Ca2+ release channel (RYR2) and the SR binding 
protein calsequestrin type 2 (CASQ2) respectively. CPVT results in aberrant RYR2-mediated SR Ca
2+
 release 
precipitated by adrenergic stress. The leaky RyR2-Ca2+ release initiates delayed afterdepolarisations (DADs) that 
might trigger polymorphic VT.  
 
Initial findings that flecainide prevented ventricular arrhythmia in two patients with respective CASQ2 and RYR2 
mutations in exercise stress tests suggested a mechanism involving reduced triggering activity (Watanabe et al., 2009). 
These clinical effects were corroborated by further case reports in which flecainide was added to prior conventional β-
adrenergic antagonist therapy (Biernacka and Hoffman, 2011; Pott et al., 2011; Jacquemart et al., 2012; Mantziari et 
al., 2013; Wangüemert-Pérez et al., 2014).  
 
Combination therapy using a β-adrenergic antagonist and flecainide partially or completely suppressed ventricular 
arrhythmias in 76 % of one CASQ2 and 32 RYR2 mutation carriers with intractable CPVT (Van Der Werf et al., 2011). 
It also completely suppressed exercise-induced ventricular arrhythmia in all of 10 CASQ2-D307H patients who were 
experiencing exercise-induced events on β-blocker therapy alone or in combination with a Ca2+ channel antagonist. 
This remission was maintained in  8 of the 10 patients over a ~15 month follow-up period (Khoury et al., 2013). 
Furthermore, addition of flecainide completely prevented ventricular arrhythmias during exercise testing and over 
long-term follow-up in 7 of 12 patients with RYR2, CASQ2 or KCNJ2 genotype-negative CPVT resistant to 
conventional β-blocker therapy (Watanabe et al., 2013). 
 
Flecainide monotherapy was pursued in patients carrying RyR2 mutations in which one patient did not tolerate β-
blockers, and 7 other patients were switched to flecainide monotherapy from combined therapy. Monotherapy with 
flecainide proved more effective or equal to β-blocker monotherapy, while combination therapy only proved more 
successful in 2 of the 8 patients over a ~37 months follow up period (Padfield et al., 2016).  
 
The paediatric CPVT phenotype is often more severe than the adult presentation (Hayashi et al., 2009). Flecainide was 
used in 24% of patients in a retrospective paediatric (<19 yr age) cohort study of 226 CPVT patients. Treatment 
failure never occurred in any adherent patient receiving optimal doses of both flecainide and β-blocker. Flecainide 
monotherapy was used in a limited number of 5 patients. Results then compared well with results from β-blockers, 
implantable cardioverter defibrillators and left cardiac sympathetic denervation. All these cases showed suppression of 
exercised induced events; 78% remained asymptomatic, and there was no mortality on follow-up (Roston et al., 2015). 
Proarrhythmic effects of flecainide of the kind observed in BrS have not been observed in the context of CPVT. 
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Nevertheless, given the underlying catecholaminergic trigger for CPVT, their efficacy and wide therapeutic window 
the first line of current therapy continues to utilize β-blocker monotherapy. However, β-blockers are not well tolerated 
or do not have an adequate therapeutic efficacy in as many as 30% of cases. These are often the younger, healthier 
patients. In these situations the addition of flecainide as a combined therapy may prove more effective. Thus, 
flecainide is an appealing therapeutic addition to traditional β-blocker monotherapy, particularly in patients resistant to 
such therapy or requiring high dose β-blockers. Adverse side effects might then be reduced through the use of smaller 
doses of two as opposed to a larger dose of a single pharmacological agent. Recent reports have progressed to 
introduce flecainide monotherapy in particular cases, with encouraging preliminary results. Flecainide monotherapy 
emerges as an available and effective next step, where β-blockers are not tolerated or ineffective. However, the current 
data relies on limited studies. Further investigation is required to conclusively assess flecainide monotherapy as an 
earlier line of treatment, given its narrow therapeutic window (Priori et al., 2013; Lieve et al., 2016). 
 
Indirect actions of flecainide on Ca
2+
-mediated triggering of arrhythmia  
Flecainide also acts upon Ca
2+
 mediated arrhythmia, as exemplified by its use in the management of CPVT outlined 
above. This action may involve cellular-level interactions following its effects upon its primary molecular targets. 
Thus, two contrasting groups of observations both suggest indirect, feed-forward effects arising from its Nav channel 
antagonism, and additionally implicate such actions in increased thresholds for triggered pro-arrhythmic activity. 
 
In the first of these, flecainide pre-treatment reduced incidences of sustained VT in RyR2-R4496C+/- mice studied by 
ECG telemetry, following epinephrine and caffeine challenge, from 70% to 8%. In isolated intact regularly paced (1 
Hz) RyR2-R4496C+/- ventricular myocytes, isoproterenol (1 µM) increased the amplitudes and accelerated the decays 
of spontaneous Ca
2+
 transients and increased SR Ca
2+
 load. Permeabilised RyR2-R4496C+/- ventricular myocytes 
similarly demonstrated greater spontaneous Ca2+ spark and wave activity than WT, particularly following 
isoproterenol challenge. Both these groups of Ca2+ release phenomena persisted with flecainide (6 µM) challenge but 
were abolished by tetracaine (Fig. 1C). Patch-clamped RyR2-R4496C+/- myocytes showed increased incidences of 
DADs and triggered activity with isoproterenol challenge. Flecainide reduced the occurrences of the triggered but not 
the DAD activity. These findings suggest flecainide actions attributable to its primary effects on Nav channel 
availability (Liu et al., 2011).  Secondly, flecainide (5 µM) reduced Ca2+ spark and wave frequency, but not amplitude, 
waveform or associated levels of SR Ca
2+
 loading in superfused, regularly-paced healthy adult rat ventricular 
myocytes. However, tetrodotoxin, propafenone (Fig. 1B) and lignocaine (Fig. 1D) exerted similar actions (Sikkel et 
al., 2013). These agents all known to decrease INa, and correspondingly reducing [Na
+
]i, could thereby decreasing 
[Ca2+]i, through an enhanced reverse mode NCX (Bers and Ellis, 1982; Eisner et al., 1984). This would decrease SR 
luminal [Ca
2+
] (Bers, 2002), reducing spontaneous SR Ca
2+
 release  (Diaz et al., 1997; Györke et al., 2004; Lindegger 
and Niggli, 2005; Sikkel et al., 2013).  
 
Direct actions of flecainide on Ca
2+
-mediated triggering of arrhythmia 
Flecainide may also act directly on SR RyR2-Ca
2+
 release channels likely through open state block (Hilliard et al. 
2011), with efficacies and potencies varying with channel activity (Savio-Galimberti and Knollmann, 2015). Open 
state RyR2 antagonism may be specific to flecainide in contrast to the prolonged RyR2 channel closure produced by 
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tetracaine (Huang, 1997; Hilliard et al., 2010; Huang et al., 2011). Flecainide would then produce optimal antagonist 
actions in association with the increased activity of ‘leaky’ CPVT as opposed to WT RyR2s. Lipid bilayer studies 
reported that flecainide antagonised WT-RyR2 opening with a half maximal inhibitory concentration (IC50) of ~15 
µM with the high luminal [Ca
2+
] expected to produce spontaneous SR Ca
2+
 release (Watanabe et al., 2009), 
reducing RyR2 open probabilities particularly when channels were in the open state (Hilliard et al., 2010). 
The IC50 values for flecainide action became progressive lower as bilayer voltage became more positive in a 
direction that would increase cation current flow from the cytoplasmic to the luminal side of the bilayer. The latter 
would correspond to a direction opposite to that expected with spontaneous Ca2+ release (Watanabe et al., 2009; 
Hilliard et al., 2010; Mehra et al., 2014). Conversely, IC50 values increased 1000-fold to mM levels at negative bilayer 
potentials that would result in a current flow from the lumen to the cytoplasm. This would correspond to a direction 
aligned with that expected for spontaneous Ca
2+
 release (Mehra et al., 2014).  Similarly in WT RyR2 exposed to 
EMD41000, consequently with high open probabilities, flecainide (10 µM) reduced cytoplasmic-to-luminal currents. 
but not luminal-to-cytosolic current even at higher (50 µM) concentrations (Bannister et al., 2015). The fully charged 
(QX-FL) and neutral (NU-FL) flecainide derivatives were less effective antagonists of cytoplasmic-to-luminal 
currents and similarly did not affect luminal-to-cytosolic current (Bannister et al., 2016).  
 
Nevertheless, flecainide may show multiple modes of RyR2 inhibition (Hwang et al., 2011; Mehra et al., 2014). Both 
cytoplasmic and luminal flecainide induced two modes of inhibition respectively associated with millisecond and 
second timescale channel closures under conditions of near-maximal RyR2 activation. The latter was achieved by the 
presence of 100 µM cytoplasmic Ca2+ and 2 mM cytoplasmic ATP. Reducing cytoplasmic free [Ca2+] to 100 nM, 
adding 1 mM free [Mg2+], and increasing (cytoplasmic – luminal) membrane potential decreased the flecainide IC50. 
Some of the differing observations may also reflect use of differing, native sheep or recombinant human, RyR2, 
preparations, levels of associated proteins, ionic conditions and directions of charge flow in the different reports. 
Finally flecainide could potentially bind calmodulin or other intermediary proteins with differing effects from those 
resulting from its direct RyR2 binding (Smith and MacQuaide, 2015).  
 
In Casq2-/- mice, flecainide pre-administration reduced incidences of ventricular arrhythmic patterns such as 
bigeminy and biventricular tachycardia (Watanabe et al., 2009). Flecainide treatment also reduced occurrences of SR 
Ca2+ release events and triggered activity in isoproterenol-treated Casq2-/- ventricular myoctes (Watanabe et al., 
2009). Permeabilised Casq2-/- ventricular myocytes demonstrated greater Ca
2+
 spark and wave activity than WT. This 
was inhibited by flecainide and R-propafenone with greater inhibitory potencies and efficacies in Casq2-/- compared 
to WT myocytes. Tetracaine contrastingly exerted similar effects in both groups. Furthermore, increasing Ca
2+
 spark 
and wave activity in WT myocytes by caffeine increased the potencies of both flecainide and propafenone but not of 
tetracaine. Other class I antiarrhythmic drugs, such as lignocaine, mexiletine and quinidine (Fig. 1D, E and F) did not 
exhibit such anti-arrhythmic efficacy in CPVT models (Savio-Galimberti and Knollmann, 2015). This difference was 
attributed to the different extents to which these test agents antagonised RyR2-mediated SR Ca
2+
 release (Hwang et 
al., 2011). Additionally, in both WT and RyR2-R4496C+/- murine Purkinje cells, flecainide suppressed spontaneous 
Ca
2+
 release events as effectively as did tetracaine (Kang et al., 2010).  
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The hypothesis in Fig. 5 summarises the above feed-forward effects of flecainide ultimately arising from its actions on 
Nav1.5. Its action in reducing peak, INa, would result in a reduction of action potential (AP) conduction velocity. This 
would exacerbate arrhythmia in BrS as the phenotype in this variant is attributable to a loss of Nav1.5 function. In 
contrast, its actions in reducing late, INaL, would reduce arrhythmia in LQTS3 as this phenotype results from a gain of 
Nav1.5 function which prolongs AP duration. Nav1.5 inhibition also increases triggering threshold. Finally a reduced 
Na
+
 entry resulting from reductions in INa reduces [Na
+
]i.  This then indirectly reduces [Ca
2+
]i through modifying NCX 
activity, in turn leading to a reduction of RyR2-mediated SR Ca2+ release and the incidence of DADs.  
 
Paradoxical effects of flecainide on arrhythmic substrate produced by RyR2-mediated Ca
2+
 release  
A final group of experiments suggested that these flecainide actions on RyR2-Ca
2+
 release channels, particularly those 
with genetic modifications related to CPVT might further reciprocally modify Nav channel function, and the 
associated AP conduction velocity, with potential implications for arrhythmic substrate. Increased [Ca
2+
]i within the 
physiological range produced concentration-dependent decreases in INa in rat ventricular cardiomyocytes (Casini et al., 
2009). This could reflect direct Ca
2+
 actions at an EF hand motif in the Nav1.5 C-terminal region (Wingo et al., 2004). 
In addition, indirect actions of Ca2+ binding may involve an IQ domain binding site for Ca2+-calmodulin (Ca2+/CaM). 
Nav1.5 also contains phosphorylatable serine, 516 and 571, and threonine, 594, sites within its DI-II linker. These are 
targeted by CaM kinase II (CaMKII) following Ca2+ binding to the EF hand motifs of calmodulin (CaM) or CaM 
kinase II (CaMKII). All these mechanisms positively shift the voltage dependence of Nav current inactivation (Wingo 
et al., 2004; Ashpole et al., 2012), and may also enhance slow Na+ current inactivation (Tan et al., 2002).  
 
RyR2-P2328S mice demonstrated isoproterenol-induced arrhythmic episodes resembling CPVT in ECG studies 
(Zhang et al., 2013). Their intact isolated Langendorff-perfused hearts showed pro-arrhythmic atrial and ventricular 
triggering and arrhythmic events associated with altered Ca2+ homeostasis during monophasic action potential 
recordings (Goddard et al., 2008; King et al., 2013b; Zhang et al., 2013). In addition, they showed arrhythmic 
substrate resulting from delayed AP conduction. Atrial multi-electrode array, and ventricular micro-electrode 
recordings following isoproterenol challenge, showed pro-arrhythmic reductions in conduction velocity compared to 
WT. Intracellular microelectrode AP recordings showed correspondingly reduced maximum rates of depolarisation 
(dV/dt)max (King et al., 2013b; Zhang et al., 2013). These changes could be attributed to (a) chronic downregulation of 
Nav1.5 expression, demonstrated in RyR2-P2328S ventricles (Ning et al., 2016) and (b) acute actions of increased 
[Ca2+]i upon Nav1.5 function. Loose-patch clamp recordings demonstrated reduced peak INa
 in whole isolated RyR2-
P2328S compared to WT atria to extents comparable to those reported in Nav1.5-haploinsufficent Scn5a+/- hearts 
(King et al., 2013a; Salvage et al., 2015) (Fig. 6A, left traces). These conduction abnormalities could not be attributed 
to either fibrotic change or altered connexin expression. The INa reductions were acutely replicated in WT atria with 
increased [Ca2+]i produced by elevated extracellular [Ca
2+], or challenge by caffeine or cyclopiazonic acid (King et al., 
2013a).  
 
Flecainide (1 µM) modified arrhythmic tendency and conduction velocity in RyR2-P2328S hearts, in directions that 
paradoxically contrasted with its corresponding effects upon either WT and Scn5a+/- hearts. It exerted pro-arrhythmic 
atrial and ventricular effects in Scn5a+/- and some WT hearts. Yet it produced consistently anti-arrhythmic effects in 
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RyR2-P2328S atria (Salvage et al., 2015). Multi-electrode recording array studies demonstrated marked conduction 
slowing in RyR2-P2328S compared to WT atria. Flecainide reduced conduction velocity and indicators of AP upstroke 
velocity in WT hearts but did not do so in RyR2-P2328S hearts (Fig. 7B left panel). RyR2-P2328S atria similarly 
showed a reduced peak INa compared to WT (Fig. 7A, left panel). However, whereas 1 µM flecainide reduced peak INa 
in WT atria, it rescued the previously reduced peak INa in RyR2-P2328S atria to magnitudes indistinguishable from 
untreated WT (Fig. 7A, centre panels) while  further increases to 5 µM flecainide inhibited INa in common with effects 
on WT (Fig. 7A, right panels). Effective refractory periods were similar in untreated RyR2-P2328S and WT atria but 
were increased in flecainide-treated RyR2-P2328S (Fig. 7B centre panel). As a result, flecainide shortened AP 
wavelength as computed from the product of conduction velocity and refractory period in WT in a direction towards 
increased arrhythmic substrate. In contrast, flecainide increased AP wavelength in RyR2-P2328S hearts consistent 
with its observed anti-arrhythmic effects (Fig. 7B, right panel) (Salvage et al., 2015).  
 
Figure 8 summarises these effects of flecainide upon arrhythmic substrate in terms of a hypothesis invoking RyR2-
P2328S as a primary pharmacological target in addition to Nav1.5. It represents an increased RyR2-mediated SR Ca
2+
 
leak associated with the RyR2-P2328S variant as exerting downregulatory effects upon Nav channel expression or 
function, thereby compromising AP conduction and potentially producing arrhythmic substrate. Flecainide is 
suggested to reduce the RyR2-mediated SR-Ca2+ leak. This would drive a feedback rescue of the compromised Nav1.5 
function, restoring INa and thereby AP conduction. This would account for a net reduction in the arrhythmic substrate 
associated with the RyR2-P2328S mutation. These findings would be consistent with dual Nav1.5 and RyR2-Ca2+ 
channel blocking effects of flecainide and propafenone (Fig. 1A, B), in contrast to selective effects of tetracaine (Fig. 
1C), and lignocaine and mexiletine (Fig. 1D,C) on RyR2 and Nav1.5 respectively, in turn consistent with patterns 
represented by their comparative chemical structures. 
 
Summary and conclusions 
The Class Ic anti-arrhythmic agent flecainide shows both pro- and anti-arrhythmic actions depending on clinical and 
experimental circumstances. Flecainide therapy had initially been introduced to suppress cardiac tachyarrhythmias 
including paroxysmal atrial fibrillation, supraventricular tachycardia and arrhythmic LQTS. It subsequently proved 
useful in the management of Ca2+-mediated arrhythmias exemplified by CPVT. However, the CAST trial reported its 
pro-arrhythmic effects following myocardial infarction. In addition, pro-arrhythmic effects of flecainide have been 
used in diagnostic tests for BrS.  
 
These divergent actions may reflect physiological and pharmacological actions of flecainide at multiple, interacting, 
levels of cellular organisation. There are also complexities in the interactions of flecainide with its primary Nav1.5 
target as well as other possible cellular targets, in particular RyR2-Ca2+ release channels. Nevertheless flecainide 
appears to act specifically through accessing a cytoplasmic binding site on Nav1.5 in its activated, open state. This 
results in a use-dependent antagonism. It also acts on other, K+ and RyR2-Ca2+ release channels, but the resulting 
antagonism appears similarly to involve open channel block. Closing either the activation or the inactivation gates in 
Nav1.5 traps flecainide within its pore. Nav1.5 function itself involves an activation which triggers the action potential 
upstroke, and inactivation that influences recovery from excitation and the refractory period. An early peak INa related 
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to Nav channel activation followed by rapid de-activation drives AP upstrokes and propagation. Peak INa is 
diminished in pro-arrhythmic conditions reflecting loss of Nav1.5 function in experimental genetic exemplars for BrS. 
Experimental data confirms predictions that these conditions would be exacerbated by the Nav1.5 inhibition 
following flecainide challenge. In contrast, the experimental data demonstrate that pro-arrhythmic phenotype effects 
attributed to abnormalities in AP recovery owing to increased INaL following the gain-of-function Nav1.5 
modifications in LQTS3 are reduced by flecainide.  
 
Anti-arrhythmic effects of flecainide on Ca
2+
 mediated arrhythmia in experimental CPVT models could arise from its 
primary Nav channel antagonism. Through NCX activity, the resulting reduced [Na+]i would indirectly decrease 
[Ca
2+
]i. Alternatively a direct open-state RyR2-Ca
2+
 channel antagonism would also reduce SR Ca
2+
 release. In both 
cases, the consequently reduced [Ca2+]i would decrease the likelihood of NCX-mediated DADs that could trigger 
arrhythmia. Such alterations in [Ca
2+
]i could also reduce the inhibitory effects of [Ca
2+
]i on Nav channel function and 
their associated effects on AP propagation velocity and arrhythmic substrate. Thus, experimental studies confirm 
predictions of paradoxical differences between flecainide actions upon Nav channel function, AP conduction and 
arrhythmia in the RyR2-P2328S model that contrast with its effects under circumstances of normal WT RyR2 
function.  
 
The apparently complex actions of flecainide upon cardiac arrhythmias are thus clarified by a systems analysis of 
actions upon different membrane proteins and their interaction with cellular Na+ and Ca2+ homeostasis, using 
experimental models for particular arrhythmic disease states. They also lead to expectations that flecainide action 
would be particularly effective in conditions associated with increased channel activity. At all events, clinical use of 
flecainide would require physiological assessment of the underlying cause of the arrhythmia.   
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Figure legends 
 
Figure 1. Chemical structures of flecainide and related pharmacological agents. 
(A) Flecainide and (B) propafenone are class Ic cardiotropic agents. (C) tetracaine is a ryanodine receptor antagonist, 
and (D) lignocaine and (E) mexiletene are class Ib cardiotropic agents. (F) quinidine is a class Ia cardiotropic agent. 
 
Figure 2.  Flecainide docking into the voltage-gated sodium channel crystal structure NavRh (pdbid: 
4DXW).  
(A). Alignment of the IV-S6 region of different voltage-gated Na+ channels, highlighting the phenylalanine residue 
(IV-S6-phe) that is strongly implicated in flecainide binding. (B). In silico docking of flecainide into NavRh locates 
the ligand in a hydrophobic pocket. The upper panels show NavRh as viewed from the top, and the lower panels as 
viewed from the side. The four colours represent the four domains that constitute the functional protein. The boxes to 
the right show the flecainide (pink) binding site represented as a cartoon. Note that as flecainide binds within the pore 
of the channel, the site has been visualised as a slice through the protein; this excludes some of the overlying helices. 
Hydrogen bond interactions (dashed red line) are predicted with IV-S6-phe. At Nav1.4 a cation-π interaction is seen at 
the same location (Ahern, Eastwood, Dougherty & Horn, 2008). (R)-Flecainide was generated ab initio using Chem3D 
Prov14.0 (CambridgeSoft, Cambridge, UK), energy minimised using the implemented MM2 force field and docked 
using GOLD Suite v5.3 (The Cambridge Crystallographic Data Centre, Cambridge, UK) with the GoldScore function 
and default settings. Amino acid sequences used in the ClustalW alignment are: 4DXW and 4EKW taken directly 
from structures of bacterial sodium channels; r_brain II = P04775; h_Nav1.1 = NP_001189364;  h_Nav1.2 = 
NP_001035232; h_Nav1.4 = NP_000325; h_Nav1.5 = NP_932173; hNav1.7 = ABI51981. 
 
Figure 3. Open state antagonism of the voltage-gated sodium channel by flecainide. 
(A) Voltage-gated Nav channel represented in its closed, resting state. Surface membrane depolarisation detected by 
the S4 segment-voltage sensor drives opening of the activation gates. This switches the channel to the (B) open state 
for a finite ~1 ms interval permitting selective Na
+
 entry. Flecainide gains access to its binding site on the cytoplasmic 
side of the channel pore thereby preventing or reducing Na+ entry into the intracellular compartment. Subsequent 
inactivation involving the cytoplasmic III-IV linker results in occlusion of the pore, and can result in (C) trapping of 
flecainide in the channel. The use-dependent action of flecainide reflects its gaining access to its binding site only 
when the channel is in the open state. Thus repetitive depolarisations that allow for the refractory period of the 
inactivated state result in higher potency.  
 
Figure 4. Rate dependent effects of flecainide on Na+ current (INa), effective refractory period (ERP), Vmax and 
APD95 in different species. 
(A) Left hand panel: superimposed Na
+
 currents, INa, recorded from HEK293 cells expressing hNav1.5 channels 
before and after application of 3 µM and 30 µM flecainide at different pulsing rates, illustrating use-dependent 
antagonism. Right hand panel: average steady-state INa inhibition by flecainide at each pulsing rate expressed as a 
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fraction of control current obtained in the absence of flecainide at that pulsing rate. IC50 of flecainide at each pacing 
rate was determined from the Hill coefficient (Adapted with permission from Fig. 6A and B of (Penniman et al., 
2010)). (B). The effects of flecainide on (from left to right): effective refractory period (ERP), maximum rate of AP 
depolarisation (Vmax) and action potential duration at 95% recovery (APD95) with changing basic cycle lengths (BCL) 
in guinea-pig, rabbit, dog and human cardiac action potentials. With decreasing BCL there was an increasing effect of 
flecainide on prolongation of both ERP and APD95, and a decreasing Vmax. (Figure adapted with permission from left 
hand panels of Figure 2, 3, and 4 of (Wang et al., 1990)).  
 
Figure 5. Feed-forward effects of flecainide attributable to its actions on Nav1.5.  
In this hypothesis, flecainide reduces peak, INa, thereby reducing action potential (AP) conduction velocity, 
exacerbating pro-arrhythmic conditions arising from loss of Nav1.5 function occurring in conditions such as BrS. In 
contrast, its reduction of late, INaL, would be anti-arrhythmic in conditions associated with gain of Nav1.5 function 
increasing INaL and prolonging AP duration such as LQTS. The inhibitory effect of flecainide on Nav1.5 also increases 
triggering threshold. Finally reduced Na
+
 entry resulting from reductions in INa reduces [Na
+
]i.  This then indirectly 
reduces [Ca2+]i through NCX action, thereby reducing incidences of RyR2-mediated SR Ca
2+ release and its resulting 
DADs.  
 
Figure 6. Flecainide actions on potassium channel subtypes 
 
Figure 7. Paradoxical actions of flecainide on Na
+
 current (INa), conduction velocity, refractory period 
and action potential (AP) wavelength in homozygotic RyR2-P2328S (RyR2
s/s
) hearts. 
(A). Loose patch clamp measurements of Na+ current, INa, in isolated atrial preparations from WT (top row) and 
RyR2
S/S
 murine hearts (bottom row) respectively demonstrate contrasting decreases and increases in peak INa with 1 
µM flecainide treatment. Increasing flecainide concentration to 5 µM resulted in a reduced INa in both RyR2
S/S and 
WT.
 
(B). Left panel: flecainide reduced conduction velocity in the WT whilst conserving conduction velocity in 
RyR2S/S atria. Centre panel: flecainide increased atrial effective refractory periods in both WT and RyR2S/S, but did so 
more markedly in the RyR2
S/S
.  Right panel: The product of conduction velocity and refractory period, wavelength (λ), 
was shorter in RyR2s/s atria than WT. However, flecainide shortened λ in WT but increased λ in RyR2s/s atria (Figure 
adapted with permission from Fig 3(a) and (b) and Fig. 7 (a)-(c) of (Salvage et al., 2015)).  
 
Figure 8. Feed-backward effects of flecainide on arrhythmic substrate attributable to its possible actions 
on RyR2-Ca
2+
 release channels.  
A model invoking RyR2-P2328S as a primary pharmacological target for flecainide in addition to Nav1.5 may account 
for its effect in diminishing arrhythmic substrate. Increased RyR2-mediated SR Ca
2+
 leak associated with RyR2-
P2328S downregulates Na+ channel expression or function, compromising AP conduction and potentially producing 
arrhythmic substrate. Reduction of the RyR2-mediated SR-Ca
2+
 leak by flecainide rescues the compromised Nav1.5 
function, restoring INa and thereby AP conduction and reduces arrhythmic substrate.  
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Fig. 4A  reproduced by permission from Fig. 6A and B of (Penniman et al., 2010) 
Figure 4B reproduced by permission from left hand panels of Figure 2, 3,4 of (Wang et al., 1990) 
Fig 6 obtained from Fig 3(a) and (b) and Fig. 7 (a)-(c) of (Salvage et al., 2015) 
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Multiple targets for flecainide action: implications for cardiac 
arrhythmogenesis 
Responses to Reviewers Comments. 
 
Reviewer: 1 
 
In the current review article, Salvage et al. elucidated that flecainide not only suppresses cardiac 
tachyarrhythmias, but also exert pro-arrhythmic effects by its involvement of modifying Na and Ca 
channels etc. This is a comprehensive review article apart from some flaws. 
 
Thank you for the positive reaction to our paper and drawing our attention to aspects requiring 
attention. We have revised the paper responding to all the reviewers’ reports, and the 
following changes are relevant to the comments made by the present reviewer. 
 
Major points: 
 
1, the authors should provide more information about combination usage of flecainide and beta-
blockers or other ion channel blockers on human or animal models. At least, this should be discussed. 
 
We have revised the relevant paragraph, concerning the use of flecainide either alone or in 
combination with beta blockers. Note the paragraph has been placed later in the review in 
response to comment 3 below. Thus for the paragraph: 
 
“More recently, flecainide was also found to exhibit potential therapeutic efficacy in the Ca
2+
-
mediated catecholaminergic polymorphic ventricular tachycardia (CPVT) (Watanabe et al). 
CPVT is predominantly associated with genetic abnormalities involving the cardiac ryanodine 
receptor type 2 sarcoplasmic reticular (SR) Ca
2+
 release channel (RYR2) and the SR binding 
protein calsequestrin type 2 (CASQ2) respectively. CPVT results in aberrant RYR2-mediated 
SR Ca2+ release precipitated by adrenergic stress. The leaky RyR2-Ca2+ release initiates 
delayed afterdepolarisations (DADs) that might trigger polymorphic VT. Initial findings that 
flecainide prevented ventricular arrhythmia in two patients with respective CASQ2 and RYR2 
mutations in exercise stress tests suggested a mechanism involving reduced triggering activity 
(Watanabe et al., 2009) and were corroborated by further case reports (Biernacka & Hoffman, 
2011; Pott et al., 2011; Jacquemart et al., 2012; Mantziari et al., 2013; Wangüemert-Pérez et 
al., 2014). Flecainide mainly used in combination with a β-adrenergic antagonist partially or 
completely suppressed ventricular arrhythmias in 76 % of one CASQ2 and 32 RYR2 mutation 
carriers with intractable CPVT (Van Der Werf et al., 2011). It suppressed exercise-induced 
ventricular arrhythmia in all of 10 and relieved symptoms in 8 of 10 CASQ2 -D307H patients 
with CPVT resistant to β-adrenergic antagonist therapy over a ~15 month follow-up period 
(Khoury et al., 2013). Flecainide treatment compared well with β-adrenergic antagonists, 
implantable cardioverter defibrillators and left cardiac sympathetic denervation in a 
retrospective paediatric (<19y age) cohort study of 226 CPVT patients (Roston et al., 2015). 
Additionally, flecainide completely prevented ventricular arrhythmias during exercise testing 
and over long-term follow-up in 7 of 12 patients with RYR2, CASQ2 or KCNJ2 genotype-
negative CPVT resistant to conventional therapy (Watanabe et al., 2013). A number of the 
above cases employed flecainide monotherapy particularly where there were significant side-
effects of β-adrenergic antagonists. Furthermore, none of a cohort of 9 patients carrying RYR2 
mutations intolerant of β-adrenergic antagonists experienced treatment failure with flecainide 
monotherapy over a ~37 months follow up period (Padfield et al., 2016). Therefore, flecainide 
is now included in treatment guidelines in patients with recurrent syncope or polymorphic 
ventricular tachycardia on β- adrenergic antagonists (Priori et al., 2013; Lieve et al., 2016).” 
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This material covering the clinical observations that flecainide acts on Ca2+ mediated arrhythmias has 
been revised to cover the background bearing on the initial use of adrenergic blockers for such 
conditions as CPVT, working through the use of combined adrenergic blocker and flecainide, to the 
more recent adoption of flecainide therapy alone. We also add a summarising paragraph unifying the 
available information. Note that in response to a further request below, we have repositioned this 
section to occur with the material on Ca2+ mediated arrhythmias:  
 
“Anti-arrhythmic effects of flecainide in catecholaminergic polymorphic ventricular 
tachycardia (CPVT) 
 
More recently, flecainide proved to exhibit potential therapeutic efficacy in the Ca
2+
-mediated 
catecholaminergic polymorphic ventricular tachycardia (CPVT). CPVT is predominantly 
associated with genetic abnormalities involving the cardiac ryanodine receptor type 2 
sarcoplasmic reticular (SR) Ca
2+
 release channel (RYR2) and the SR binding protein 
calsequestrin type 2 (CASQ2) respectively. CPVT results in aberrant RYR2-mediated SR 
Ca2+ release precipitated by adrenergic stress. The leaky RyR2-Ca2+ release initiates delayed 
afterdepolarisations (DADs) that might trigger polymorphic VT.  
 
Initial findings that flecainide prevented ventricular arrhythmia in two patients with respective 
CASQ2 and RYR2 mutations in exercise stress tests suggested a mechanism involving 
reduced triggering activity (Watanabe et al., 2009). These clinical effects were corroborated 
by further case reports in which flecainide was added to prior conventional β-adrenergic 
antagonist therapy (Biernacka & Hoffman, 2011; Pott et al., 2011; Jacquemart et al., 2012; 
Mantziari et al., 2013; Wangüemert-Pérez et al., 2014).  
 
Combination therapy using a β-adrenergic antagonist and flecainide partially or completely 
suppressed ventricular arrhythmias in 76 % of one CASQ2 and 32 RYR2 mutation carriers 
with intractable CPVT (Van Der Werf et al., 2011). It also completely suppressed exercise-
induced ventricular arrhythmia in all of 10 CASQ2-D307H patients who were experiencing 
exercise-induced events on β-blocker therapy alone or in combination with a Ca2+ channel 
antagonist. This remission was maintained in  8 of the 10 patients over a ~15 month follow-up 
period (Khoury et al., 2013). Furthermore, addition of flecainide completely prevented 
ventricular arrhythmias during exercise testing and over long-term follow-up in 7 of 12 
patients with RYR2, CASQ2 or KCNJ2 genotype-negative CPVT resistant to conventional β-
blocker therapy (Watanabe et al., 2013). 
 
Flecainide monotherapy was pursued in patients carrying RyR2 mutations in which one 
patient did not tolerate β-blockers, and 7 other patients were switched to flecainide 
monotherapy from combined therapy. Monotherapy with flecainide proved more effective or 
equal to β-blocker monotherapy, while combination therapy only proved more successful in 2 
of the 8 patients over a ~37 months follow up period (Padfield et al., 2016).  
 
The paediatric CPVT phenotype is often more severe than the adult presentation (Hayashi et 
al., 2009). Flecainide was used in 24% of patients in a retrospective paediatric (<19 yr age) 
cohort study of 226 CPVT patients. Treatment failure never occurred in any adherent patient 
receiving optimal doses of both flecainide and β-blocker. Flecainide monotherapy was used in 
a limited number of 5 patients. Results then compared well with results from β-blockers, 
implantable cardioverter defibrillators and left cardiac sympathetic denervation. All these 
cases showed suppression of exercised induced events; 78% remained asymptomatic, and 
there was no mortality on follow-up (Roston et al., 2015). Proarrhythmic effects of flecainide 
of the kind observed in BrS have not been observed in the context of CPVT. 
 
Nevertheless, given the underlying catecholaminergic trigger for CPVT, their efficacy and 
wide therapeutic window the first line of current therapy continues to utilize β-blocker 
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monotherapy. However, β-blockers are not well tolerated or do not have an adequate 
therapeutic efficacy in as many as 30% of cases. These are often the younger, healthier 
patients. In these situations the addition of flecainide as a combined therapy may prove more 
effective. Thus, flecainide is an appealing therapeutic addition to traditional β-blocker 
monotherapy, particularly in patients resistant to such therapy or requiring high dose β-
blockers. Adverse side effects might then be reduced through the use of smaller doses of two 
as opposed to a larger dose of a single pharmacological agent. Recent reports have progressed 
to introduce flecainide monotherapy in particular cases, with encouraging preliminary results. 
Flecainide monotherapy emerges as an available and effective next step, where β-blockers are 
not tolerated or ineffective. However, the current data relies on limited studies. Further 
investigation is required to conclusively assess flecainide monotherapy as an earlier line of 
treatment, given its narrow therapeutic window (Priori et al., 2013; Lieve et al., 2016).” 
 
Note: the following points emerging from the initial case reports make clear the grounds upon which 
we have summarized the situation concerning flecainide/beta-block combination therapy versus 
flecainide monotherapy: these early studies all involved combined therapy with monotherapy 
occurring later in a more limited group of reported cases.  
 
a) (Biernacka & Hoffman, 2011): one patient unable to tolerate propranolol so the 
patient was given a combined flecainide and bisoprolol regime. Effective suppression 
of exertion induced arrhythmia after 3 days. 
b) (Pott et al., 2011): Flecainide added to beta blocker/verapamil treatment as the initial 
treatment was ineffective at arrhythmia suppression. BB dose was subsequently 
reduced but not stopped. 
c) (Jacquemart et al., 2012) Flecainide added to beta blocker therapy as the BB was not 
effective alone. The combination was a success. 
d) (Mantziari et al., 2013) combination therapy- metoprolol and flecainide with 
implantable defibrillator. 
e) (Padfield et al., 2016): One patient who did not tolerate BB therapy whatsoever and 
seven patients who were removed from BB therapy (total 8 patients). Transition from 
beta blocker to flecainide monotherapy occurred over a 2-8 week period.  
 
2, Schematic figure should also be provided for information of K channel antagonism by flecainide. 
 
We have provided New figure 6, to cover flecainide actions on K+ channels, with a re-
arrangement of the text so the section on flecainide actions of K+ channels occurs in a more 
logical place. 
Flecainide challenge
Kv1.5
↑? APD 
(atria)
↓ IKur
Kv11.1
↑ APD 
(atria and 
ventricles)
↓ IKr
↑ APD/ERP 
ratio; long QT)
Kv4.2
↑ ?APD 
(atria and 
ventricles)
↓ Ito(f)
Figure 6
 
New Figure 6. Flecainide actions on potassium channel subtypes.  
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We have also made good a number of omissions in our nomenclature so the passage: 
 
“K+ channel antagonism by flecainide 
“Flecainide also acts on K
+
 channels, where it inhibits rapid K
+
 current, IKR, tails that followed 
voltage clamp pulses to +30 mV in the HEK293 expression system. The effect was most 
noticeable in the steepest part of the IKR activation curve reflecting a voltage-dependent 
inhibition consistent with a rapid open channel state IKR antagonism similar to that described 
for INa (Paul et al., 2002). Flecainide also inhibits rapid transient outward currents, Itof, in both 
native cells (Slawsky & Castle, 1994) and heterologous expression systems (Rolf et al., 
2000), to extents increasing with channel inactivation and consistent with its higher affinity 
for the inactivated state of Kv4.2 (Wang et al., 1995). Finally, flecainide inhibits ultrarapid 
delayed rectifier, IKur with preference for current carried by Kv3.1 over human Kv1.5 (Herrera 
et al., 2005)” 
 
Is modified to (with clarification of K+ channel molecular types and flecainide concentrations 
and an additional reference(Tamargo et al., 2004)):  
 
“K+ channel antagonism by flecainide 
Flecainide also acts on K
+
 channels (Figure 6). At <10 µM it inhibits rapid K
+
 current, IKR, 
tails that followed voltage clamp pulses to +30 mV in the HEK293 expression system. The 
effect was most noticeable in the steepest part of the IKR  (Kv11.1, hERG) activation curve 
reflecting a voltage-dependent inhibition consistent with a rapid open channel state IKR 
antagonism similar to that described for INa (Paul et al., 2002). Flecainide (>10 µM) also 
inhibits rapid transient outward (Kv4.2) currents, Itof, in both native cells (Slawsky & Castle, 
1994) and heterologous expression systems (Rolf et al., 2000), to extents increasing with 
channel inactivation and consistent with its higher affinity for the inactivated state of Kv4.2 
(Wang et al., 1995). Finally, flecainide  (~100 µM) inhibits ultrarapid delayed rectifier 
(Kv1.5) current, IKur (Tamargo et al., 2004; Herrera et al., 2005)” 
 
 “ 
3, Logically, restructure of article writing is highly suggested. The authors should 
demonstrate anti-arrhythmic effects and pro-arrhythmic effects of flecainide by clinical levels 
followed by molecular (channels’ alterations) for each part. 
 
As requested, there has been a rearrangement of topics as suggested with each major section 
preceded by clinical findings, and this is then followed by possible molecular and 
physiological mechanisms. This involves a re-arrangement of material covering clinical 
observations that flecainide acts on Ca
2+
 mediated arrhythmias so that it precedes the 
experimental data exploring its mechanisms. The relevant paragraph (which was one that was 
revised as described above) is:  
 
““More recently, flecainide proved to exhibit potential therapeutic efficacy in the Ca2+-
mediated catecholaminergic polymorphic ventricular tachycardia (CPVT). CPVT is 
predominantly associated with….. However, the current data relies on limited studies. Further 
investigation is required to conclusively assess flecainide monotherapy as an earlier line of 
treatment, given its narrow therapeutic window (Priori et al., 2013; Lieve et al., 2016).” 
 
 
Reviewer: 2 
 
The review entitled ‘multiple targets for flecainide action: implications for cardiac arrhythmogenesis’ 
summarises and synthesises the complex actions of the Class Ic anti-arrhythmic drug flecainide on the 
mammalian heart.  The review takes a mechanistic approach and discusses what is known about the 
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modes of interaction between the drug and its primary targets – Nav1.5 and RyR2. The review 
summaries the relevant data and has chosen appropriate ‘case studies’ for inclusion in figures. The 
paper also makes a strong attempt to pull apart the multiple and often conflicting actions of flecainide 
on arrhythmias.  The authors propose a feed-forward and feed-backward schema to integrate the 
diverse physiological, biophysical and pharmacological data with clinical findings.  My suggestions 
for improvement are minor and are listed below. 
 
Thank you for the positive reaction to our paper, encapsulating our objectives so effectively 
and advising us about aspects requiring attention. We have revised the paper responding to all 
the reviewers’ reports. The following changes are relevant to the comments made by the 
present reviewer. 
 
P5  paragraph 2 second last sentence – remove one of the ‘over a 10 month period’ statements. 
 
Thank you:  the passage: 
 
“However, over a 10 month follow-up, encainide or flecainide-treated patients showed a higher 
incidence (8.9%) of arrhythmic death than patients assigned to placebo (1.2%) over a 10 month 
follow-up (CAST Investigators, 1989; Echt et al., 1991; Greenberg et al., 1995).” 
 
Is now corrected to: 
 
“However, encainide or flecainide-treated patients showed a higher incidence (8.9%) of 
arrhythmic death than patients assigned to placebo (1.2%) over a 10 month follow-up (CAST 
Investigators, 1989; Echt et al., 1991; Greenberg et al., 1995).” 
 
P5 top of page – does this need to start with ‘However’? Perhaps just begin the paragraph with The 
Nav channel…. 
 
Thank you: The passage:  
“However, even Nav
 
channel function itself poses intrinsic complexities.” 
 Is corrected to: 
 “The Nav channel function itself poses intrinsic complexities.” 
 
Same paragraph – can you explain how INa ‘may compromise on of more currents components each 
with different kinetics’ 
 
Thanks. The word should have been ‘comprise’ rather than ‘compromise’ and the passage reads: 
“Secondly, the resulting Na+ current, INa, may comprise one or more current components each 
with different kinetics.” 
 
However, the wording has been improved to: 
“Secondly, the resulting Na
+
 current, INa, may include one or more current components each with 
different kinetics.” 
 
P5 Bottom of second paragraph – may be useful to explain more what is meant by absolute and 
relative refractory periods. 
 
Thank you. We have incorporated definitions of absolute and relative refractory periods into the 
revised text as suggested:  
 
The passage: 
 
 “Finally, with repolarisation to the resting potential, the Nav1.5 channels recover their capacity 
for re-excitation over absolute and relative refractory periods.”  
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Is now clarified to: 
 
“Finally, with repolarisation to the resting potential, the Nav1.5 channels recover their capacity 
for re-excitation, resulting in absolute and relative refractory periods. These respectively 
correspond to the time intervals over which the channels either cannot be re-excited whatever the 
stimulus intensity, or require increased stimulus amplitudes for such re-excitation.” 
 
P5 3rd paragraph – the idea of protein complexes influencing channel function could be expanded 
upon here to lead better into the later discussion of flecainide interactions with B3-subunits. 
 
Thank you. We identify the point at issue as existing at the paragraphs: 
 
(A) “Further complexities arise from Nav channel anchoring into localised plasma 
membrane clusters within larger, extended protein complexes. These include not only 
auxiliary Nav channel β subunits (Cusdin et al., 2010), but also cytoskeletal proteins  
(Jeevaratnam et al., 2016; Huang, 2017) and even other ion channels such as the 
inward rectifier Kir2.1 (Willis et al., 2015). These associated proteins can influence 
Nav channel gating behaviour both directly through protein-protein contacts and 
indirectly by affecting surface expression and trafficking (Abriel & Kass, 2005; 
Cusdin et al., 2008).” 
 
And: 
 
(B) “As noted above, Nav channels in vivo are associated with a range of auxiliary and 
interacting proteins, many of which can modulate channel gating. However, relatively 
little attention has been paid to this particular aspect of flecainide pharmacology. To 
our knowledge, the only example where effects of auxiliary subunits on flecainide 
behaviour were studied is the case of the β3 subunit, the product of the Scn3b gene  
(Hakim et al., 2010). The β3 subunit is expressed in heart and modulates Nav1.5 
gating (Yu et al., 2005). The β3 subunit contains a single extracellular 
immunoglobulin domain, a single-pass transmembrane domain and an intracellular 
domain. It interacts with Nav1.5 through both its extracellular and intracellular 
domains (Namadurai et al., 2015). However, neither of these two interaction sites are 
close to the flecainide binding site on Nav1.5 (Fig.  2B). Nevertheless, β3 could 
potentially modulate the effects of flecainide on Nav1.5 indirectly, either affecting 
channel opening probability or by its known effects on Nav1.5 oligomerisation 
(Namadurai et al., 2014, 2015).“ 
 
And:  
 
(C) “Patch-clamped Scn3b
-/- 
murine cardiomyocytes showed reduced INa likely reflecting 
reduced Nav1.5 trafficking into the surface membrane. This was combined with 
negative shifts in Nav1.5 inactivation characteristics that would be expected to reduce 
INaL but shorten refractory periods. The genetic variant accordingly shows arrhythmic 
phenotypes resembling that of the Scn5a+/- murine model (Hakim et al., 2008). 
Indeed, several mutations in SCN3B are associated with inherited cardiac arrhythmias 
in humans (Namadurai et al., 2015). However, in contrast to its effects in Scn5a+/-, in 
Scn3b-/- hearts, flecainide produced reduced arrhythmic incidences combined with 
prolonged refractory periods and shortened APDs (Hakim et al., 2010). The reasons 
for this difference are unclear, but they further confirm suggestions that flecainide 
exerts dual pro- and anti-arrhythmic actions through both conduction and 
refractoriness effects. Thus, in the case of Scn5a+/- hearts the negative conduction 
velocity effects predominate in producing arrhythmia exacerbated by flecainide. In the 
case of LQTS3, refractoriness and recovery effects predominate in producing 
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arrhythmia reduced by flecainide. The presence or absence of β3 subunits may 
differentially modify these two competing effects so that an anti-arrhythmic effect 
predominates.“ 
 
We have rewritten and relocated these paragraphs to (1) expand the idea of protein complexes 
influencing channel function to (2) lead better into the later revised discussion of flecainide 
interactions with β3-subunits to: 
 
“Further complexities arise because Nav channels do not occur as isolated molecules in 
the plasma membrane, but instead are anchored within larger, extended multi-component 
complexes. Examples of such associated proteins include auxiliary Nav channel β subunits 
(Cusdin et al., 2010), cytoskeletal proteins  (Jeevaratnam et al., 2016; Huang, 2017) and 
other ion channels such as the inward rectifier Kir2.1 (Willis et al., 2015). These proteins 
can influence Nav channel gating behaviour both directly through protein-protein contacts 
and indirectly by affecting surface expression and trafficking (Abriel & Kass, 2005; 
Cusdin et al., 2008; Abriel et al., 2015). 
 
 Relatively little attention has been paid to how this supra-molecular channel clustering 
could influence flecainide pharmacology. To our knowledge, the only example where such 
effects on flecainide behaviour were studied is the case of the auxiliary Nav β3 subunit, the 
product of the Scn3b gene  (Hakim et al., 2010). The β3 subunit is expressed in heart and 
modulates Nav1.5 gating (Yu et al., 2005). Patch-clamped Scn3b
-/- 
murine cardiomyocytes 
showed reduced INa likely reflecting reduced Nav1.5 trafficking into the surface 
membrane. This was combined with negative shifts in Nav1.5 inactivation characteristics 
that would be expected to reduce INaL but shorten refractory periods. The genetic variant 
accordingly shows arrhythmic phenotypes resembling that of the Scn5a+/- murine model 
(Hakim et al., 2008). Indeed, seve al mutations in SCN3B are associated with inherited 
cardiac arrhythmias in humans (Namadurai et al., 2015).  
 
Curiously however, in Scn3b-/- hearts, flecainide produced reduced arrhythmic incidences 
combined with prolonged refractory periods and shortened APDs (Hakim et al., 2010). 
This is in direct contrast to its effects in Scn5a+/- mice (see above). The reasons for this 
difference are unclear, but they further confirm suggestions that flecainide exerts dual pro- 
and anti-arrhythmic actions through effects on both conduction and refractoriness. Thus, in 
the case of Scn5a+/- hearts the negative conduction velocity effects predominate in 
producing arrhythmia exacerbated by flecainide. In the case of LQTS3, refractoriness and 
recovery effects predominate in producing arrhythmia reduced by flecainide. The presence 
or absence of β3 subunits may differentially modify these two competing effects so that an 
anti-arrhythmic effect predominates.  
 
How this might work is currently unknown and will probably require detailed structural 
insights into how the β3 subunit interacts and modulates the Nav1.5 α subunit. The β3 
subunit contains a single extracellular immunoglobulin domain, a single-pass 
transmembrane domain and an intracellular domain and interacts with Nav1.5 through 
both its extracellular and intracellular domains (Namadurai et al., 2015). It is striking 
however, that neither of these two interaction sites are close to the flecainide binding site 
on Nav1.5 (Fig.  2B). This suggests that the β3 subunit most likely modulates the effects of 
flecainide on Nav1.5 indirectly, either by affecting channel opening probability or by its 
known effects on Nav1.5 oligomerisation (Namadurai et al., 2014, 2015).” 
 
P7 3rd paragraph – which ‘confounding complexities’ are you referring to here? 
 
Thank you. This sentence:  
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“Confounding these complexities further are the elaborate actions of flecainide upon 
the Nav channel, each with implications for channel activation and recovery.” 
 
 Is indeed unclear, and in fact is completely unnecessary. It has been omitted and the 
paragraph now begins with the next sentence: 
 
 “Flecainide acts upon the activated, open, state of Nav1.5 (Anno & Hondeghem, 1990; 
Nitta et al., 1992; Nagatomo et al., 2000)…” 
 
 P10 top of page – i am not clear from this paragraph what the action of flecainide on the B3 subunit 
is?  Or how it affects Ina function.  May be worth trying to rephrase this paragraph. 
 
We have dealt with this issue under a query above [ “P5 3rd paragraph – the idea of protein 
complexes influencing channel function could be expanded upon here to lead better into the 
later discussion of flecainide interactions with B3-subunits.”]. Briefly we point out that little is 
known about the effect of flecainide on beta subunits. 
 
“How this might work is currently unknown and will probably require detailed structural 
insights into how the β3 subunit interacts and modulates the Nav1.5 α subunit. The β3 
subunit contains a single extracellular immunoglobulin domain, a single-pass 
transmembrane domain and an intracellular domain and interacts with Nav1.5 through 
both its extracellular and intracellular domains (Namadurai et al., 2015). It is striking 
however, that neither of these two interaction sites are close to the flecainide binding site 
on Nav1.5 (Fig.  2B). This suggests that the β3 subunit most likely modulates the effects of 
flecainide on Nav1.5 indirectly, either by affecting channel opening probability or by its 
known effects on Nav1.5 oligomerisation (Namadurai et al., 2014, 2015).” 
 
 
Figure legend 2 – I don’t see hydrogen bonds in the figure? 
 
We have changed the figure in response to the comment that no hydrogen bonds were 
visible. We have also taken the opportunity to slightly simplify. The new figure and its 
legend are as below; we deleted a few words to make the legend compatible with the 
new fig: 
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Fig 2.  Flecainide docking into the voltage-gated sodium channel crystal structure 
NavRh (pdbid: 4DXW). (A). Alignment of the IV-S6 region of different voltage-gated 
Na+ channels, highlighting the phenylalanine residue (IV-S6-phe) that is strongly 
implicated in flecainide binding. (B). In silico docking of flecainide into NavRh locates 
the ligand in a hydrophobic pocket. The upper panels show NavRh as viewed from the 
top, and the lower panels as viewed from the side. The four colours represent the four 
domains that constitute the functional protein. The boxes to the right show the 
flecainide (pink) binding site represented as a cartoon. Note that as flecainide binds 
within the pore of the channel, the site has been visualised as a slice through the 
protein; this excludes some of the overlying helices. Hydrogen bond interactions 
(dashed red line) are predicted with IV-S6-phe. At Nav1.4 a cation-π interaction is seen 
at the same location (Ahern, Eastwood, Dougherty & Horn, 2008). (R)-Flecainide was 
generated ab initio using Chem3D Prov14.0 (CambridgeSoft, Cambridge, UK), energy 
minimised using the implemented MM2 force field and docked using GOLD Suite v5.3 
(The Cambridge Crystallographic Data Centre, Cambridge, UK) with the GoldScore 
function and default settings. Amino acid sequences used in the ClustalW alignment 
are: 4DXW and 4EKW taken directly from structures of bacterial sodium channels; 
r_brain II = P04775; h_Nav1.1 = NP_001189364;  h_Nav1.2 = NP_001035232; 
h_Nav1.4 = NP_000325; h_Nav1.5 = NP_932173; hNav1.7 = ABI51981. 
 
Figure legend 4 – add brackets around (ERP) in title for consistency and around (B) later in the 
paragraph. 
 
(1) The title of figure legend 4 is corrected from” Rate dependent effects of flecainide on 
Na
+
 current (INa), effective refractory period ERP, Vmax and APD95 in different 
species.“ to “Rate dependent effects of flecainide on Na
+
 current (INa), effective 
refractory period (ERP), Vmax and APD95 in different species.“ 
 
(2) Brackets placed around “B” in “B. The effects of flecainide on (from left to right):” to 
give “(B). The effects of flecainide on (from left to right):” 
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